Literature DB >> 19013005

Identification of primary MAFB target genes in multiple myeloma.

Esther van Stralen1, Marc van de Wetering, Luca Agnelli, Antonino Neri, Hans C Clevers, Bert J E G Bast.   

Abstract

OBJECTIVE: In multiple myeloma (MM), seven primary recurrent translocations involving the immunoglobulin heavy chain locus have been identified. One of the partner loci maps to 20q12 and involves the MAFB gene resulting in its ectopic expression. We attempt here to identify MAFB target genes in MM.
MATERIALS AND METHODS: We used an inducible system to upregulate MAFB in MM cell lines not carrying the t(14;20). Microarray expression analysis was used to detect gene expression changes upon MAFB expression. These genes were further evaluated comparatively with gene expression profiles obtained from MM or plasma cell leukemia tumors carrying an activated MAFB gene. Functional implications of these upregulated genes were studied by testing their promoter activity in reporter assays. C-MAF was included comparatively as well.
RESULTS: The inducible cell lines identified a total of 284 modulated transcripts. After further evaluation using ex vivo data 14 common upregulated genes were found, common to the C-MAF pathway as well. The promoter activity of some of these secondary genes proved a functional relationship with MAFB. In connection with one of these secondary genes (NOTCH2), even tertiary upregulated genes were found. Functional studies indicated that inducible MAFB expression conferred antiapoptotic effects.
CONCLUSION: We identified 14 upregulated genes, and their downstream consequences in the combined MAFB/C-MAF pathway. Eleven of these genes are novel in the C-MAF pathway as well. These direct target genes may be responsible for the oncogenic transformation of MAF expressing myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19013005     DOI: 10.1016/j.exphem.2008.08.006

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  24 in total

1.  DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Authors:  Timothy R Peterson; Mathieu Laplante; Carson C Thoreen; Yasemin Sancak; Seong A Kang; W Michael Kuehl; Nathanael S Gray; David M Sabatini
Journal:  Cell       Date:  2009-05-14       Impact factor: 41.582

2.  Association of ABCA4 and MAFB with non-syndromic cleft lip with or without cleft palate.

Authors:  Qiuping Yuan; Susan H Blanton; Jacqueline T Hecht
Journal:  Am J Med Genet A       Date:  2011-05-12       Impact factor: 2.802

3.  Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.

Authors:  Gary Lu; Ramya Muddasani; Robert Z Orlowski; Lynne V Abruzzo; Muzaffar H Qazilbash; M James You; Yaping Wang; Ming Zhao; Su Chen; Isabella Claudia Glitza; L Jeffrey Medeiros
Journal:  Arch Pathol Lab Med       Date:  2013-05       Impact factor: 5.534

Review 4.  MafA and MafB activity in pancreatic β cells.

Authors:  Yan Hang; Roland Stein
Journal:  Trends Endocrinol Metab       Date:  2011-06-28       Impact factor: 12.015

5.  DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia.

Authors:  Y Hu; H Su; C Liu; Z Wang; L Huang; Q Wang; S Liu; S Chen; J Zhou; P Li; Z Chen; H Liu; G Qing
Journal:  Oncogene       Date:  2016-09-05       Impact factor: 9.867

6.  Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.

Authors:  Paola Neri; Li Ren; Abdel Kareem Azab; Matthew Brentnall; Kathy Gratton; Alexander C Klimowicz; Charles Lin; Peter Duggan; Pierfrancesco Tassone; Adnan Mansoor; Douglas A Stewart; Lawrence H Boise; Irene M Ghobrial; Nizar J Bahlis
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

Review 7.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

8.  Overexpression of Mafb in podocytes protects against diabetic nephropathy.

Authors:  Naoki Morito; Keigyou Yoh; Masami Ojima; Midori Okamura; Megumi Nakamura; Michito Hamada; Homare Shimohata; Takashi Moriguchi; Kunihiro Yamagata; Satoru Takahashi
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

9.  The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival.

Authors:  Yuanming He; Siyu Wang; Jiefei Tong; Shuoyi Jiang; Ye Yang; Zubin Zhang; Yujia Xu; Yuanying Zeng; Biyin Cao; Michael F Moran; Xinliang Mao
Journal:  J Biol Chem       Date:  2019-12-10       Impact factor: 5.157

10.  Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.

Authors:  Alexandra Pisklakova; Eileen Grigson; Maria Ozerova; Feng Chen; Daniel M Sullivan; Yulia Nefedova
Journal:  Cancer Biol Ther       Date:  2016-03-02       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.